Immune Mechanisms and Pathways Targeted in Type 1 Diabetes.

Current Diabetes Reports
Laura M JacobsenTodd M Brusko

Abstract

The immunosuppressive agent cyclosporine was first reported to lower daily insulin dose and improve glycemic control in patients with new-onset type 1 diabetes (T1D) in 1984. While renal toxicity limited cyclosporine's extended use, this observation ignited collaborative efforts to identify immunotherapeutic agents capable of safely preserving β cells in patients with or at risk for T1D. Advances in T1D prediction and early diagnosis, together with expanded knowledge of the disease mechanisms, have facilitated trials targeting specific immune cell subsets, autoantigens, and pathways. In addition, clinical responder and non-responder subsets have been defined through the use of metabolic and immunological readouts. Herein, we review emerging T1D biomarkers within the context of recent and ongoing T1D immunotherapy trials. We also discuss responder/non-responder analyses in an effort to identify therapeutic mechanisms, define actionable pathways, and guide subject selection, drug dosing, and tailored combination drug therapy for future T1D trials.

References

Nov 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·Z J ZhangH L Weiner
Oct 1, 1982·Acta diabetologica latina·J Ludvigsson, L Heding
May 31, 2002·The New England Journal of Medicine·UNKNOWN Diabetes Prevention Trial--Type 1 Diabetes Study Group
Feb 25, 2003·Archives of Disease in Childhood·N WilkinsonJ Gardner-Medwin
Mar 27, 2004·Lancet·E A M GaleUNKNOWN European Nicotinamide Diabetes Intervention Trial (ENDIT) Group
Mar 11, 2005·The New England Journal of Medicine·Dino VeneriEnzo Bonora
Jun 29, 2005·Diabetes Care·Jay S SkylerUNKNOWN Inhaled Insulin Phase III Type 1 Diabetes Study Group
Dec 1, 2005·Proceedings of the National Academy of Sciences of the United States of America·Shannon J TurleyChristophe Benoist
Apr 12, 2007·JAMA : the Journal of the American Medical Association·Júlio C VoltarelliRichard K Burt
May 12, 2007·The Review of Diabetic Studies : RDS·Frantisek SaudekJelena Skibova
Aug 7, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Masakazu KobayashiKatsumi Eguchi
Oct 10, 2008·The New England Journal of Medicine·Johnny LudvigssonRosaura Casas
Dec 26, 2008·The New England Journal of Medicine·Maria J RedondoTihamer Orban
Jan 6, 2009·Annals of the New York Academy of Sciences·Júlio C VoltarelliRichard K Burt
May 12, 2009·Nature Genetics·Jeffrey C BarrettUNKNOWN Type 1 Diabetes Genetics Consortium
Jun 30, 2009·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Piotr TrzonkowskiAndrzej Hellmann
Sep 2, 2009·Proceedings of the National Academy of Sciences of the United States of America·René MaehrDouglas A Melton
Sep 11, 2009·PloS One·Akio KurodaKevin Ferreri
Oct 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirk R SchultzBruce Camitta
Nov 27, 2009·The New England Journal of Medicine·Mark D PescovitzUNKNOWN Type 1 Diabetes TrialNet Anti-CD20 Study Group
May 5, 2010·Acta Diabetologica·Douglas O SobelVal Abbassi
Sep 11, 2010·Diabetes/metabolism Research and Reviews·Stina AxelssonRosaura Casas
Sep 28, 2010·Diabetologia·M SchlosserUNKNOWN Participating Laboratories
Nov 4, 2010·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Maria HjorthRosaura Casas
Jan 12, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·A SchölinUNKNOWN Diabetes Incidence Study Group in Sweden (DISS)
Feb 2, 2011·The Journal of Allergy and Clinical Immunology·Jan LötvallPaul A Greenberger

❮ Previous
Next ❯

Citations

Oct 11, 2019·International Journal of Molecular Sciences·Carla Di DeddaPaolo Monti
Sep 20, 2019·Nature Reviews. Endocrinology·Jorma IlonenRiitta Veijola
Dec 29, 2018·British Journal of Hospital Medicine·Christopher J Schofield, Calum Sutherland
Jul 17, 2020·Frontiers in Endocrinology·Marina PrimaveraFrancesco Chiarelli
Jul 12, 2020·Microorganisms·Shirin GeravandiKathrin Maedler
Sep 11, 2020·Tissue Engineering. Part B, Reviews·Rachel E GurlinEsther Latres
Aug 25, 2020·Diabetes Technology & Therapeutics·Laura M JacobsenMichael J Haller
Nov 3, 2020·World Journal of Diabetes·Rui-Feng MaoYe-Fu Wang
Mar 24, 2021·Reviews in Endocrine & Metabolic Disorders·Federico Boscari, Angelo Avogaro
May 21, 2021·ESC Heart Failure·Cheng-Ju TianZhong Zhen
Oct 20, 2021·ACS Applied Materials & Interfaces·Shaojingya GaoYunfeng Lin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Cellular Immunometabolism

Immunometabolism involves not only the way metabolites are digested by the immune system, but the way in which they can alter the pathway of the immune system. These responses occur in day-to-day healthy cell functioning, but can result in diseases, such as autoimmune disorders. Discover the latest research on cellular immunometabolism here.

Related Papers

The New England Journal of Medicine
Denise L Faustman
Current Opinion in Endocrinology, Diabetes, and Obesity
James E Tooley, Kevan C Herold
Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Sergio DellepianePaolo Fiorina
Expert Opinion on Orphan Drugs
Mark A ApplebaumSusan L Cohn
© 2022 Meta ULC. All rights reserved